Jiang, Cheng http://orcid.org/0000-0003-4583-3295
DiLeone, Ralph J. http://orcid.org/0000-0002-4770-2590
Pittenger, Christopher http://orcid.org/0000-0003-2117-9321
Duman, Ronald S. http://orcid.org/0000-0001-8690-8439
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH127259, MH093897, MH093897)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS101104)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P30DA018343)
Article History
Received: 21 July 2023
Revised: 16 January 2024
Accepted: 19 January 2024
First Online: 12 February 2024
Competing interests
: RSD consulted and/or received research support from Allergan, Naurex, Aptinyx, Sunovian, Eli Lilly, Johnson & Johnson, Taisho, Relmada, and Navitor. CP serves as a consultant and/or receives research support from Biohaven Pharmaceuticals, Ceruvia Lifesciences, Freedom Biosciences, Transcend Therapeutics, Nobilis Therapeutics, UCB BioPharma, Teva Pharmaceuticals, Lundbeck Therapeutics, and F-Prime Capital Partners. He owns equity in Alco Therapeutics, receives royalties and/or honoraria from Oxford University Press, Elsevier, and Up-To-Date, and has filed a patent on the use of psilocybin in the treatment of OCD, irrelevant to the current work. CJ and RJD report no biomedical financial interests or potential conflicts of interest.